1. Pink Sheet

FTC Merger Guidelines Cast ‘Perilous Shadow’ Over Biopharma

 
• By Brenda Sandburg

BIO objects to guidelines seeking to block mergers that would eliminate a potential entrant in a concentrated market and give greater scrutiny to transactions that are part of a series of company deals. APhA and NCPA call for FTC to consider more factors in PBM mergers.

Merger shadow
BIO and others recommend changes to FTC-DOJ proposed revision to merger guidelines. • Source: Shutterstock

The Biotechnology Innovation Organization is urging the US Federal Trade Commission to reconsider proposed revisions to merger guidelines, arguing that they would be “catastrophic” to the industry.

BIO objects to the directive that mergers should not eliminate a potential entrant in a concentrated market and the guideline...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Compliance

EU-Level Efforts To Mitigate Drug Shortages Unsuccessful, Audit Reveals

 
• By Eliza Slawther

Actions taken by the European Commission and European Medicines Agency to tackle critical shortages of medicines have not succeeded in practice and further systemic improvements are required to address supply issues, a report from the European Court of Auditors has found.

‘Major Statements’ Are Major Target Of US FDA’s New TV Ad Crackdown

 
• By Sarah Karlin-Smith, Cathy Kelly, and Derrick Gingery

The bolus of untitled letters signals the FDA's approach to enforcement of the final rule on the presentation of the major statement in direct-to-consumer TV ads in a clear, conspicuous and neutral matter.

DTC Ad Crackdown: US FDA Focuses On Compounded GLP-1 Marketers

 
• By Cathy Kelly and Sue Sutter

Just eight of the 68 warning letters posted by the FDA to date went to innovator companies, but GLP-1 agonists still were a focus.

EU’s Draft GMP Guideline Signals Major Cultural Shift In Pharma Quality Compliance

 
• By Vibha Sharma

While the EU's draft good manufacturing practice guideline on pharmaceutical quality systems reflects modern quality management principles, it also presents significant operational and resource challenges for drug companies.

More from Pink Sheet

ACIP Weakened COVID-19 Vaccine Advice, But Less Than Rhetoric May Suggest

 
• By Sarah Karlin-Smith

The new recommendations should not change insurance coverage, but the tone of the meeting frustrated many medical experts, because of the negative comments on the vaccines.

Inexperience And Confusion: ACIP Struggles To End MMRV, Hep B Debates

 
• By Bridget Silverman

Confusion, inconsistency and strongly held views complicated the CDC's Advisory Committee on Immunization Practices' votes to change vaccine recommendations for the measles, mumps, rubella, varicella vaccine in young children and tabling of a vote on hepatitis B vaccine at birth.

US FDA Appears To Be Managing MAHA Well By Feeding Instead Of Receiving Priorities

 
• By Ramsey Baghdadi

The newly issued Make America Healthy Again strategy report suggests that FDA leaders are doing a good job of feeding ideas to the Trump Administration, rather than having the agency agenda dictated from above.